EU Regulator To Re-Examine Safety Of Common Drugs

Law360, New York (September 26, 2006, 12:00 AM EDT) -- Europe’s top drug agency has launched another review of commonly used anti-inflammatory drugs amid concerns over a link to heightened risk of heart attacks.

The European Medicines Agency (EMA) said on Tuesday that it was launching a new review on non-selective non-steroidal anti-inflammatory drugs (NSAIDs), reversing an earlier stance that gave NSAIDs a clean bill of health.

EMA will present a scientific opinion next month to address the benefit-risk profile of the drugs, the agency said.

NSAIDs are widely used to treat arthritis and other painful...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.